|
Allele Symbol Allele Name Allele ID |
Tg(LPV-TAg1135)11Tvd transgene insertion 11, Terry Van Dyke MGI:2386975 |
||||||||||||||||||||||||||||||||||||
| Summary |
8 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival time at which half of the mutants are sacrificed or die due to illness is 165 days
|
|
• 100% incidence of thymoma
|
|
• 100% incidence of thymoma
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival time at which half of the mutants are sacrificed or die due to illness is 238 days
|
|
• 85% incidence of thymoma
• tumors arise more slowly or with longer latency than in single hemizygous Tg(LPV-TAg1135)11Tvd mice, with mutants living 44% longer than controls
|
|
• inactive V(D)J recombination
|
|
• inactive V(D)J recombination
|
|
• 85% incidence of thymoma
• tumors arise more slowly or with longer latency than in single hemizygous Tg(LPV-TAg1135)11Tvd mice, with mutants living 44% longer than controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival time at which half of the mutants are sacrificed or die due to illness is 167 days
|
|
• 83% incidence of thymoma
• tumors arise more slowly or with longer latency than in single hemizygous Tg(LPV-TAg1135)11Tvd mice, with mutants living 14% longer than controls
|
|
• 83% incidence of thymoma
• tumors arise more slowly or with longer latency than in single hemizygous Tg(LPV-TAg1135)11Tvd mice, with mutants living 14% longer than controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival time at which half of the mutants are sacrificed or die due to illness is 146 days
|
|
• 100% incidence of thymoma
|
|
• 100% incidence of thymoma
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival time at which half of the mutants are sacrificed or die due to illness is 101 days
|
|
• 100% of mutants develop thymic lymphoma within the same accelerated time frame as mutants heterozygous for Rag1 and hemizygous for the two transgenes
|
|
• 100% of mutants develop thymic lymphoma within the same accelerated time frame as mutants heterozygous for Rag1 and hemizygous for the two transgenes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival time at which half of the mutants are sacrificed or die due to illness is 110 days
|
|
• 100% incidence of thymoma
• tumorigenesis is accelerated compared to mice hemizygous for Tg(LPV-TAg1135)11Tvd and heterozygous for Rag1
|
|
• 100% incidence of thymoma
• tumorigenesis is accelerated compared to mice hemizygous for Tg(LPV-TAg1135)11Tvd and heterozygous for Rag1
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival time at which half of the mutants are sacrificed or die due to illness is 210 days
|
|
• 62% incidence of thymoma, however tumor development is not accelerated compared to heterozygous Prkdc and hemizygous Tg(LPV-TAg1135)11Tvd mice, and is actually slightly delayed
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• survival time at which half of the mutants are sacrificed or die due to illness is 183 days
|
|
• 93% incidence of thymoma
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||
Analysis Tools